Local control and patterns of failure for “Radioresistant” spinal metastases following stereotactic body radiotherapy compared to a “Radiosensitive” reference

Purpose The concept of a radioresistant (RR) phenotype has been challenged with use of stereotactic body radiotherapy (SBRT). We compared outcomes following SBRT to RR spinal metastases to a radiosensitive cohort. Methods Renal cell, melanoma, sarcoma, gastro-intestinal, and thyroid spinal metastase...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2021-03, Vol.152 (1), p.173-182
Main Authors: Zeng, K. Liang, Sahgal, Arjun, Husain, Zain A., Myrehaug, Sten, Tseng, Chia-Lin, Detsky, Jay, Sarfehnia, Arman, Ruschin, Mark, Campbell, Mikki, Foster, Monica, Das, Sunit, Lipsman, Nir, Bjarnason, Georg A., Atenafu, Eshetu G., Maralani, Pejman Jabehdar, Soliman, Hany
Format: Article
Language:English
Subjects:
Clinical Study
Compression
Epidural
Intestine
Liver diseases
Lung diseases
Magnetic resonance imaging
Medicine
Medicine & Public Health
Melanoma
Metastases
Metastasis
Neurology
Oncology
Phenotypes
Prostate cancer
Radiation therapy
Sarcoma
Spine
Thyroid
Vertebrae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The concept of a radioresistant (RR) phenotype has been challenged with use of stereotactic body radiotherapy (SBRT). We compared outcomes following SBRT to RR spinal metastases to a radiosensitive cohort. Methods Renal cell, melanoma, sarcoma, gastro-intestinal, and thyroid spinal metastases were identified as RR and prostate cancer (PCA) as radiosensitive. The primary endpoint was MRI-based local failure (LF). Secondary endpoints included overall survival (OS) and vertebral compression fracture (VCF). Results From a prospectively maintained database of 1394 spinal segments in 605 patients treated with spine SBRT, 173 patients/395 RR spinal segments were compared to 94 patients/185 PCA segments. Most received 24–28 Gy in 2 fractions (68.9%) and median follow-up was 15.5 months (range, 1.4–84.2 months). 1- and 2-year LF rates were 19.2% and 22.4% for RR metastases, respectively, which were significantly greater (p 
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-020-03691-6